mut. BRAF sel. heterobifunctional degrader
efficacy in xenograft at 50 mg/kg IP BID
VHL-based degrader from vemurafenib
Nat. Comm., Feb. 10, 2021
Yale University, New Haven, CT
SJF-0628
13. The Yale BRAF-targeting PROTAC SJF-0628 is a VHL-based heterobifunctional degrader with in vivo activity in a xenograft model (50 mg/kg BID IP). Though mutant BRAF is a well-validated…